BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

373 related articles for article (PubMed ID: 16969289)

  • 1. Assessment of the risk of chronic allograft dysfunction after renal transplantation in a randomized cyclosporine withdrawal trial.
    Hazzan M; Buob D; Labalette M; Provot F; Glowacki F; Hoffmann M; Copin MC; Noel C
    Transplantation; 2006 Sep; 82(5):657-62. PubMed ID: 16969289
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Minimization of maintenance immunosuppression early after renal transplantation: an interim analysis.
    Bemelman FJ; de Maar EF; Press RR; van Kan HJ; ten Berge IJ; Homan van der Heide JJ; de Fijter HW
    Transplantation; 2009 Aug; 88(3):421-8. PubMed ID: 19667948
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical outcomes during the first three months posttransplant in renal allograft recipients managed by C2 monitoring of cyclosporine microemulsion.
    Thervet E; Pfeffer P; Scolari MP; Toselli L; Pallardó LM; Chadban S; Pilmore H; Connolly J; Buchler M; Schena FP; Carreño CA; Dandavino R; Cole E
    Transplantation; 2003 Sep; 76(6):903-8. PubMed ID: 14508352
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of sirolimus plus tacrolimus versus sirolimus plus cyclosporine in high-risk renal allograft recipients: results from an open-label, randomized trial.
    Gaber AO; Kahan BD; Van Buren C; Schulman SL; Scarola J; Neylan JF;
    Transplantation; 2008 Nov; 86(9):1187-95. PubMed ID: 19005398
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized controlled study comparing reduced calcineurin inhibitors exposure versus standard cyclosporine-based immunosuppression.
    Hernández D; Miquel R; Porrini E; Fernández A; González-Posada JM; Hortal L; Checa MD; Rodríguez A; García JJ; Rufino M; Torres A
    Transplantation; 2007 Sep; 84(6):706-14. PubMed ID: 17893603
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase III prospective, randomized study to evaluate concentration-controlled sirolimus (rapamune) with cyclosporine dose minimization or elimination at six months in de novo renal allograft recipients.
    Baboolal K
    Transplantation; 2003 Apr; 75(8):1404-8. PubMed ID: 12717239
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunosuppression modifications and graft outcome in patients with chronic allograft nephropathy.
    El-Agroudy AE; El-Dahshan K; Mahmoud K; Ismail AM; El-Baz M; Shokeir AA; Ghoneim MA
    Exp Clin Transplant; 2008 Sep; 6(3):203-10. PubMed ID: 18954298
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized study comparing cyclosporine with azathioprine one year after renal transplantation-15-year outcome data.
    Joss N; Rodger RS; McMillan MA; Junor BJ
    Transplantation; 2007 Mar; 83(5):582-7. PubMed ID: 17353778
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cyclosporine reduction in the presence of everolimus: 3-month data from a Canadian pilot study of maintenance cardiac allograft recipients.
    Ross H; Pflugfelder P; Haddad H; Cantarovich M; White M; Ignaszewski A; Howlett J; Vaillancourt M; Dorent R; Burton JR;
    J Heart Lung Transplant; 2008 Feb; 27(2):197-202. PubMed ID: 18267227
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early cyclosporine withdrawal from a sirolimus-based regimen results in better renal allograft survival and renal function at 48 months after transplantation.
    Oberbauer R; Segoloni G; Campistol JM; Kreis H; Mota A; Lawen J; Russ G; Grinyó JM; Stallone G; Hartmann A; Pinto JR; Chapman J; Burke JT; Brault Y; Neylan JF;
    Transpl Int; 2005 Jan; 18(1):22-8. PubMed ID: 15612979
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cyclosporine A withdrawal during follow-up after pediatric liver transplantation.
    Scheenstra R; Torringa ML; Waalkens HJ; Middelveld EH; Peeters PM; Slooff MJ; Gouw AS; Verkade HJ; Bijleveld CM
    Liver Transpl; 2006 Feb; 12(2):240-6. PubMed ID: 16447209
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial.
    Schena FP; Pascoe MD; Alberu J; del Carmen Rial M; Oberbauer R; Brennan DC; Campistol JM; Racusen L; Polinsky MS; Goldberg-Alberts R; Li H; Scarola J; Neylan JF;
    Transplantation; 2009 Jan; 87(2):233-42. PubMed ID: 19155978
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictive factors of acute rejection after early cyclosporine withdrawal in renal transplant recipients who receive mycophenolate mofetil: results from a prospective, randomized trial.
    Hazzan M; Labalette M; Copin MC; Glowacki F; Provôt F; Pruv FR; Noël C
    J Am Soc Nephrol; 2005 Aug; 16(8):2509-16. PubMed ID: 15987748
    [TBL] [Abstract][Full Text] [Related]  

  • 14. One-year observation of kidney allograft recipients converted from cyclosporine microemulsion to tacrolimus.
    Chamienia A; Biedunkiewicz B; Król E; Debska-Slizień A; Rutkowski B
    Transplant Proc; 2006; 38(1):81-5. PubMed ID: 16504670
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cyclosporine-based immunosuppressive strategies for kidney recipients: interim analysis of German data from the Multinational Observational Study (MOST).
    Kliem V; Fritsche L; Haller H; Suwelack B; Abendroth D; Fornara P; Pietruck F; Frei U; Donauer J; Lison AE; Michel U; Ulbricht B;
    Transplant Proc; 2005 Apr; 37(3):1597-600. PubMed ID: 15866683
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An open randomized study comparing immunosuppression therapy initiated before or after kidney transplantation in haploidentical living recipients.
    Câmara NO; Dias MF; Pacheco-Silva A
    Clin Transplant; 2004 Aug; 18(4):450-5. PubMed ID: 15233825
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Variable cyclosporine exposure: a risk factor for chronic allograft nephropathy and graft loss?
    He X; Johnston A
    Transplant Proc; 2004 Jun; 36(5):1321-6. PubMed ID: 15251323
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term results of a prospective randomized study comparing two immunosuppressive regimens, one with and one without CsA, in low-risk renal transplant recipients.
    Grimbert P; Baron C; Fruchaud G; Hemery F; Desvaux D; Buisson C; Chopin D; Dahmane D; Remy P; Pastural M; Abbou C; Weil B; Lang P
    Transpl Int; 2002 Nov; 15(11):550-5. PubMed ID: 12461659
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Peritubular capillary C4d staining in late acute renal allograft rejection--is it relevant?
    Satoskar AA; Lehman AM; Nadasdy GM; Sedmak DD; Pesavento TE; Henry ML; Pelletier RP; Ferguson RM; Nadasdy T
    Clin Transplant; 2008; 22(1):61-7. PubMed ID: 18217907
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Acute rejection in cadaveric renal transplantation under cyclosporine based therapy. Analysis of the risk factors and its influence on chronic dysfunction].
    Mota A
    Acta Med Port; 2004; 17(1):8-14. PubMed ID: 15636737
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.